INDIANAPOLIS (dpa-AFX) - Eli Lilly And Co. (LLY) announced on Tuesday that it will spend $6.5 billion to construct a manufacturing plant in Houston, Texas, with the goal of increasing production of its pipeline of small molecule medications, which includes the much-discussed experimental obesity medication orforglipron.
In addition to the $23 billion invested since 2020, the project is a part of a larger $27 billion plan to add four new plants in the United States. Lilly plans to reveal the remaining two sites later this year, and all four sites should start producing medications within five years.
In order to boost production of its pipeline of small molecule drugs, which includes the highly debated experimental obesity drug orforglipron, Eli Lilly said Tuesday that it would invest $6.5 billion to build a manufacturing facility in Houston, Texas.
The project is a component of a larger $27 billion plan to add four new plants in the United States, on top of the $23 billion invested since 2020.
All four locations should begin manufacturing drugs within five years, and Lilly intends to unveil the other two later this year.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
